66 related articles for article (PubMed ID: 37625240)
1. Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients.
Yu JH; Xiao BY; Tang JH; Li DD; Wang F; Ding Y; Han K; Kong LH; Ling YH; Mei WJ; Hong ZG; Liao LE; Yang WJ; Pan ZZ; Zhang XS; Jiang W; Ding PR
Eur J Cancer; 2023 Oct; 192():113253. PubMed ID: 37625240
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
[TBL] [Abstract][Full Text] [Related]
3. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
[TBL] [Abstract][Full Text] [Related]
7. Deficient mismatch repair screening of advanced adenomas in the population screening program for colorectal cancer is not effective.
Vink-Börger E; Dabir PD; Krekels J; van Kouwen MCA; Ligtenberg MJL; van der Post RS; Nagtegaal ID
Histopathology; 2024 May; 84(6):1056-1060. PubMed ID: 38275207
[TBL] [Abstract][Full Text] [Related]
8. Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters.
Hashmi AA; Bukhari U; Rizwan R; Faisal F; Kumar R; Malik UA; Zia S; Khan AR; Sham S; Irfan M
Cureus; 2023 Aug; 15(8):e42781. PubMed ID: 37664303
[TBL] [Abstract][Full Text] [Related]
9. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
Cai L; Chen A; Tang D
Immunology; 2024 Mar; ():. PubMed ID: 38517066
[TBL] [Abstract][Full Text] [Related]
10. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade.
Harrold EC; Foote MB; Rousseau B; Walch H; Kemel Y; Richards AL; Keane F; Cercek A; Yaeger R; Rathkopf D; Segal NH; Patel Z; Maio A; Borio M; O'Reilly EM; Reidy D; Desai A; Janjigian YY; Murciano-Goroff YR; Carlo MI; Latham A; Liu YL; Walsh MF; Ilson D; Rosenberg JE; Markowitz AJ; Weiser MR; Rossi AM; Vanderbilt C; Mandelker D; Bandlamudi C; Offit K; Berger MF; Solit DB; Saltz L; Shia J; Diaz LA; Stadler ZK
Nat Med; 2023 Oct; 29(10):2458-2463. PubMed ID: 37845474
[TBL] [Abstract][Full Text] [Related]
11. ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer.
Zhang D; Ni QQ; Liang QY; He LL; Qiu BW; Zhang LJ; Mou TY; Le CC; Huang Y; Li TT; Wang SY; Ding YQ; Jiao HL; Ye YP
Oncogene; 2023 Sep; 42(38):2841-2853. PubMed ID: 37591954
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.
Fox DA; Bhamidipati D; Konishi T; Kaur H; You N; Raghav KPS; Ge PS; Messick C; Johnson B; Morris VK; Thomas JV; Shah P; Bednarski BK; Kopetz S; Chang GJ; Ludford K; Higbie VS; Overman MJ
Eur J Cancer; 2023 Nov; 194():113356. PubMed ID: 37827065
[TBL] [Abstract][Full Text] [Related]
13. Does breast carcinoma belong to the Lynch syndrome tumor spectrum? - Somatic mutational profiles vs. ovarian and colorectal carcinomas.
Porkka NK; Olkinuora A; Kuopio T; Ahtiainen M; Eldfors S; Almusa H; Mecklin JP; Peltomäki P
Oncotarget; 2020 Apr; 11(14):1244-1256. PubMed ID: 32292574
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
[TBL] [Abstract][Full Text] [Related]
15. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
Wang D; Zhang H; Xiang T; Wang G
Front Immunol; 2021; 12():762341. PubMed ID: 34721435
[TBL] [Abstract][Full Text] [Related]
16. Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome.
Eslinger C; Walden D; Barry T; Shah S; Samadder NJ; Bekaii-Saab TS
J Natl Compr Canc Netw; 2023 Sep; 21(9):894-899. PubMed ID: 37673116
[TBL] [Abstract][Full Text] [Related]
17. Immunology of Lynch Syndrome.
Pastor DM; Schlom J
Curr Oncol Rep; 2021 Jun; 23(8):96. PubMed ID: 34125344
[TBL] [Abstract][Full Text] [Related]
18. Lynch Syndrome-Associated Glioblastoma Treated With Concomitant Chemoradiotherapy and Immune Checkpoint Inhibitors: Case Report and Review of Literature.
Nakase K; Matsuda R; Sasaki S; Nakagawa I
Brain Tumor Res Treat; 2024 Jan; 12(1):70-74. PubMed ID: 38317491
[TBL] [Abstract][Full Text] [Related]
19. Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation.
Chen J; Liu J; Liu X; Wang J; Wang X; Ye X; Xie Q; Liang J; Li Y
Mol Biol Rep; 2024 Jan; 51(1):86. PubMed ID: 38183539
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway.
Xu X; Lv J; Guo F; Li J; Jia Y; Jiang D; Wang N; Zhang C; Kong L; Liu Y; Zhang Y; Lv J; Li Z
Front Microbiol; 2020; 11():814. PubMed ID: 32425919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
